215 related articles for article (PubMed ID: 22338609)
1. Statistical considerations of optimal study design for human plasma proteomics and biomarker discovery.
Zhou C; Simpson KL; Lancashire LJ; Walker MJ; Dawson MJ; Unwin RD; Rembielak A; Price P; West C; Dive C; Whetton AD
J Proteome Res; 2012 Apr; 11(4):2103-13. PubMed ID: 22338609
[TBL] [Abstract][Full Text] [Related]
2. Comparative proteomics, network analysis and post-translational modification identification reveal differential profiles of plasma Con A-bound glycoprotein biomarkers in gastric cancer.
Uen YH; Lin KY; Sun DP; Liao CC; Hsieh MS; Huang YK; Chen YW; Huang PH; Chen WJ; Tai CC; Lee KW; Chen YC; Lin CY
J Proteomics; 2013 May; 83():197-213. PubMed ID: 23541716
[TBL] [Abstract][Full Text] [Related]
3. Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling.
Pan S; Chen R; Crispin DA; May D; Stevens T; McIntosh MW; Bronner MP; Ziogas A; Anton-Culver H; Brentnall TA
J Proteome Res; 2011 May; 10(5):2359-76. PubMed ID: 21443201
[TBL] [Abstract][Full Text] [Related]
4. Multiplexed, Quantitative Workflow for Sensitive Biomarker Discovery in Plasma Yields Novel Candidates for Early Myocardial Injury.
Keshishian H; Burgess MW; Gillette MA; Mertins P; Clauser KR; Mani DR; Kuhn EW; Farrell LA; Gerszten RE; Carr SA
Mol Cell Proteomics; 2015 Sep; 14(9):2375-93. PubMed ID: 25724909
[TBL] [Abstract][Full Text] [Related]
5. A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer.
Tang HY; Beer LA; Chang-Wong T; Hammond R; Gimotty P; Coukos G; Speicher DW
J Proteome Res; 2012 Feb; 11(2):678-91. PubMed ID: 22032327
[TBL] [Abstract][Full Text] [Related]
6. A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ.
Tonack S; Aspinall-O'Dea M; Jenkins RE; Elliot V; Murray S; Lane CS; Kitteringham NR; Neoptolemos JP; Costello E
J Proteomics; 2009 Dec; 73(2):352-6. PubMed ID: 19651253
[TBL] [Abstract][Full Text] [Related]
7. Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry.
Yu KH; Rustgi AK; Blair IA
J Proteome Res; 2005; 4(5):1742-51. PubMed ID: 16212428
[TBL] [Abstract][Full Text] [Related]
8. Quantitative, multiplexed workflow for deep analysis of human blood plasma and biomarker discovery by mass spectrometry.
Keshishian H; Burgess MW; Specht H; Wallace L; Clauser KR; Gillette MA; Carr SA
Nat Protoc; 2017 Aug; 12(8):1683-1701. PubMed ID: 28749931
[TBL] [Abstract][Full Text] [Related]
9. Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer.
Pietrowska M; Marczak L; Polanska J; Behrendt K; Nowicka E; Walaszczyk A; Chmura A; Deja R; Stobiecki M; Polanski A; Tarnawski R; Widlak P
J Transl Med; 2009 Jul; 7():60. PubMed ID: 19594898
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 4-plex to 8-plex iTRAQ quantitative measurements of proteins in human plasma samples.
Pottiez G; Wiederin J; Fox HS; Ciborowski P
J Proteome Res; 2012 Jul; 11(7):3774-81. PubMed ID: 22594965
[TBL] [Abstract][Full Text] [Related]
11. High throughput and accurate serum proteome profiling by integrated sample preparation technology and single-run data independent mass spectrometry analysis.
Lin L; Zheng J; Yu Q; Chen W; Xing J; Chen C; Tian R
J Proteomics; 2018 Mar; 174():9-16. PubMed ID: 29278786
[TBL] [Abstract][Full Text] [Related]
12. A large, consistent plasma proteomics data set from prospectively collected breast cancer patient and healthy volunteer samples.
Riley CP; Zhang X; Nakshatri H; Schneider B; Regnier FE; Adamec J; Buck C
J Transl Med; 2011 May; 9():80. PubMed ID: 21619653
[TBL] [Abstract][Full Text] [Related]
13. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
Yoneyama T; Ohtsuki S; Honda K; Kobayashi M; Iwasaki M; Uchida Y; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Huang W; Yamada T; Tachikawa M; Terasaki T
PLoS One; 2016; 11(8):e0161009. PubMed ID: 27579675
[TBL] [Abstract][Full Text] [Related]
14. Proteomic Biomarker Discovery in 1000 Human Plasma Samples with Mass Spectrometry.
Cominetti O; Núñez Galindo A; Corthésy J; Oller Moreno S; Irincheeva I; Valsesia A; Astrup A; Saris WH; Hager J; Kussmann M; Dayon L
J Proteome Res; 2016 Feb; 15(2):389-99. PubMed ID: 26620284
[TBL] [Abstract][Full Text] [Related]
15. A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discovery.
Villanueva J; Nazarian A; Lawlor K; Yi SS; Robbins RJ; Tempst P
Mol Cell Proteomics; 2008 Mar; 7(3):509-18. PubMed ID: 17986438
[TBL] [Abstract][Full Text] [Related]
16. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.
Fiedler GM; Leichtle AB; Kase J; Baumann S; Ceglarek U; Felix K; Conrad T; Witzigmann H; Weimann A; Schütte C; Hauss J; Büchler M; Thiery J
Clin Cancer Res; 2009 Jun; 15(11):3812-9. PubMed ID: 19470732
[TBL] [Abstract][Full Text] [Related]
17. Discovery of serum protein biomarkers for prostate cancer progression by proteomic analysis.
Al-Ruwaili JA; Larkin SE; Zeidan BA; Taylor MG; Adra CN; Aukim-Hastie CL; Townsend PA
Cancer Genomics Proteomics; 2010; 7(2):93-103. PubMed ID: 20335524
[TBL] [Abstract][Full Text] [Related]
18. Mixed-mode ion exchange-based integrated proteomics technology for fast and deep plasma proteome profiling.
Xue L; Lin L; Zhou W; Chen W; Tang J; Sun X; Huang P; Tian R
J Chromatogr A; 2018 Aug; 1564():76-84. PubMed ID: 29935814
[TBL] [Abstract][Full Text] [Related]
19. Proteomic investigation on bio-corona of Au, Ag and Fe nanoparticles for the discovery of triple negative breast cancer serum protein biomarkers.
Del Pilar Chantada-Vázquez M; López AC; Vence MG; Vázquez-Estévez S; Acea-Nebril B; Calatayud DG; Jardiel T; Bravo SB; Núñez C
J Proteomics; 2020 Feb; 212():103581. PubMed ID: 31731051
[TBL] [Abstract][Full Text] [Related]
20. Experimental Null Method to Guide the Development of Technical Procedures and to Control False-Positive Discovery in Quantitative Proteomics.
Shen X; Hu Q; Li J; Wang J; Qu J
J Proteome Res; 2015 Oct; 14(10):4147-57. PubMed ID: 26051676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
